Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J’s Galantamine Controlled-Release Formulation Offers Dosing Parity With Aricept

This article was originally published in The Pink Sheet Daily

Executive Summary

Janssen's recently approved extended-release capsule version of galantamine (formerly Reminyl) gives it dosing parity with Pfizer/Eisai's Aricept (donepezil)

You may also be interested in...



Janssen To Change Name Of Reminyl Products

Janssen agreed to change the brand name for galantamine products due to continued confusion with Aventis' Amaryl, which has resulted in medication errors. The company will submit new proposed names to FDA for review.

Italy Leads European Push Into Conditional Reimbursement

Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.

Topics

UsernamePublicRestriction

Register

PS058479

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel